Drug intelligence / Profile preview

CLP2-ADC

Development stage: Preclinical
Lead developer: ChemPartner
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CLP2-ADC is a preclinical antibody-drug conjugate (ADC) developed by ChemPartner. It utilizes a novel linker technology (CLP2) designed to tailor the Drug-to-Antibody Ratio (DAR) and incorporate multiple payloads, which serves as a potential solution to drug resistance. In preclinical studies, CLP2-ADC targeting HER2-positive cancers demonstrated enhanced therapeutic efficacy in resistant cell lines compared to reference ADCs. It is being investigated for the treatment of HER2-positive breast and gastric cancers.

Targets

TOP1 (DNA Topoisomerase I)TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on CLP2-ADC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLP2-ADC.

Explore the full profile